Boston Scientific beats Q1 revenue expectations, except for endoscopy sales

US-based Boston Scientific has publicized its first quarter report, which surpassed analysts’ revenue expectations.

Photo: Marcio Jose Sanchez/AP/Ritzau Scanpix

US-based medtech firm Boston Scientific, a competitor of Danish firm Ambu on the endoscopy market, has delivered Q1 results on both top and bottom lines that exceed estimations, though according to these, endoscopy sales have underperformed slightly.

Following the report’s publication, the company’s stock went up by 3.3 percent in the premarket.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs